



INFORMATION DISCLOSURE STATEMENT

(Use Several Sheets if necessary)

ATTY DOCKET NO.

60364 A

SERIAL NO.

10/031,792

APPLICANT

R.K. Frank et al.

FILING DATE

February 23, 2001

GROUP

Unknown

1616

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
<i>LD</i>	5,428,154	Jun. 27, 1995	Gansow et al	540	465	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
<i>LD</i> 99/30745	Jun. 24, 1999	PCT	A61K	51/00	
<i>LD</i> 00/59896	Oct. 12, 2000	PCT	C07D	259/00	
<i>LD</i> 02/05859	Jan. 24, 2002	PCT	A61K	51/04	

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, Place of Publication, Etc.)

<i>LD</i>	McDevitt et al, "A novel Alpha Particle Emitting ²²⁵ Ac Labeled Anti-CD33 Antibody Construct: Synthesis and <i>In Vitro</i> Evaluation of Biochemistry, Potency, Specificity, and Mechanism of Cell Death," <u>Journal of Nuclear Medicine</u> , Vol. 41 No. 5, May 2000, pp. 3P.
<i>LD</i>	Scheinberg et al, "Clinical Application of Targeted Alpha Particles for Cancer Therapy," <u>Chemical Abstract Service & Book of Abstracts</u> , 215 th ACS Meeting, Dallas, March 29-April 2 (1998), American Chemical Society Publishers.

EXAMINER

HARTLEY

DATE CONSIDERED

6/3/2004

*EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to Applicant.